Patients who combine semaglutide with permanent dietary habit changes (lower refined carbohydrate intake, higher protein, consistent calorie awareness) often maintain 5070% of their losses long-term
While not directly cardiac, this represents an important safety consideration
None of this changes the bottom line: no completed human clinical trial exists for any BPC-157 indication
Once a treatment plan is in place, patients have ongoing access to the care team for dose guidance, side-effect management, and questions at no additional charge
Chronic inflammation caused by autoimmune diseases can increase oxidative stress
You should not use Wegovy if you or an immediate family member has ever had medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN 2)